Busulfan (busulfan): Reviews and patient testimonials

Busulfan 2 mg tablets

Busulfan is indicated as conditioning treatment prior to haemopoietic progenitor cell transplantation in patients when the combination of high-dose busulfan and cyclophosphamide is considered the best available option.

Busulfan is indicated for the palliative treatment of the chronic phase of chronic myeloid leukaemia.

Busulfan is effective in producing prolonged remission in polycythaemia vera, particularly in cases with marked thrombocytosis.

Busulfan may be useful in selected cases of essential thrombocythaemia and myelofibrosis.

Busulfan 6 mg/ml concentrate for solution for infusion

Busulfan Injection followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.

Busulfan Injection following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen.

Busulfan Injection followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.